Marinus Pharmaceuticals Inc (FRA:61Y)
€ 0.302 0.002 (0.67%) Market Cap: 17.09 Mil Enterprise Value: 30.25 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 37/100

Marinus Pharmaceuticals Inc R&D Day Transcript

Oct 05, 2021 / 01:00PM GMT
Release Date Price: €10.1 (-0.98%)
Sasha Damouni Ellis
Marinus Pharmaceuticals, Inc. - VP of Corporate Affairs & IR

Good morning, and welcome to the Marinus Pharmaceuticals 2021 R&D Day. My name is Sasha Damouni Ellis, and I'm Vice President, Corporate Affairs and Investor Relations at Marinus. This morning, members of our leadership team will discuss the company's clinical development program, pipeline expansion opportunities, commercial strategy and reformulation initiatives.

Our CEO, Scott Braunstein, will lead with an overview of recent accomplishments, upcoming milestones and overall corporate goals. Dr. Joe Hulihan, our Chief Medical Officer, will discuss our IV ganaxolone clinical development program as well as updates across the continuum and status epilepticus. Dr. Alex Aimetti, Vice President, Scientific Affairs, will discuss our oral ganaxolone clinical development strategy, including commentary on plans for the upcoming Phase III clinical trials in tuberous sclerosis complex. Dr. Ian Miller, Vice President, Clinical Development, will give an overview of the unmet need in pediatric epilepsies and potential

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot